US OptionsDetailed Quotes

SLS250117C3000

Watchlist
  • 0.05
  • 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

News

Comments

    我要向钱看
    我要向钱看
    Jan 8 19:39
    UPDATES
    $Sellas Life Sciences (SLS.US)$ SELLAS Life Sciences Group (NASDAQ: SLS) outlined key business objectives for 2025, highlighting two major upcoming milestones. The company expects an interim analysis of its Phase 3 REGAL study by an Independent Data Monitoring Committee in January 2025, which will determine whether to stop the trial early for efficacy, stop for futility, or continue without modification.
    Additionally, full topline Phase 2 data for SLS009 (tambiciclib) in Acute Myeloid Leu...
    Jaguar8
    Jaguar8
    Dec 10, 2024 07:57
    NEWS
    $Sellas Life Sciences (SLS.US)$
    SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
    Tuesday, 10th December at 8:30 am
    -  Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis –
    -  REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 -
    -  Company to Host Webcast Call Today at 9:00 am ET
    NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: ...
    Trytosaveabit
    Trytosaveabit
    Dec 9, 2024 07:47
    Update
    $Sellas Life Sciences (SLS.US)$ SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
    2 MINUTES AGO, 8:45 AM EST
    VIA GLOBENEWSWIRE
    Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
    - Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Relat...
    Jaguar8
    Jaguar8
    Dec 9, 2024 07:45
    NEWS
    $Sellas Life Sciences (SLS.US)$
    SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
    Monday, 9th December at 8:45 am
    - Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
    - Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AM...
    Jaguar8
    Jaguar8
    Dec 8, 2024 16:31
    SLS presenting in ASH Conference
    $Sellas Life Sciences (SLS.US)$
    “SELLAS Life Sciences To Present Phase 2a Data On SLS009 For Relapsed/Refractory AML At ASH 2024, Showing 50% Response Rate And Median OS Of 5.5 Months At Selected Doses”
Read more